Hello Monkeys,
Anyone whose in the HC team at Wells Fargo, I would love to gain more insight within the group, especially in the NYC group. How is the dealflow/culture/senior management/compensation like?
And as for deals, do you mostly work on Financing, M&A or Capital Raises (IPO/SPACs).
| +260 | Why UBS Is the Worst Place to Start Your IB Career | 40 | 1d |
| +216 | UBS 2nd Year Analyst Q&A (2026) | 41 | 5h |
| +94 | What's your craziest "hardo" story? | 16 | 14h |
| +62 | Indiana University Fraternity Pipelines | 36 | 2d |
| +52 | Rogo AI | 22 | 8h |
| +49 | Elite Boutique interview questions | 17 | 1d |
| +48 | Suspended for a Year | 19 | 3d |
| +47 | Wolf of Wall Street vs. Reality: Anyone else feel scammed by the movies? | 18 | 7h |
| +30 | Rate my non-target resume | 15 | 8h |
| +24 | RX Firm Lateral Advice | 15 | 12h |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
Bump
Bump
Bump, anybody know what exits look like?
One of the weaker coverage teams at Wells. I think they made a recent senior hire (don’t know what group HASNT) from Barclays? Heard he’s a hardo lmao.
Any idea what bonuses are like if they are one of the weaker coverage teams?
It looks like they hired D. Campili from Barclays London this spring as vice chair but coincidentally lost J. Birchenough (chairman) to Barclays this summer…so I guess Campili got an auto promo or maybe it was always planned?
Any insight on him or any of the healthcare practice’s other MD/D/VP-level team?
@OP, did you learn anything more about this group?
Still looking for more information; been seeing quite some churn within the group. Would love to know more about the deal flow/culture of the group
Darren is one of the nicest and most personable bankers you’ll meet.
Weakest coverage group at WF based on league tables.
Do you know what their total fees are for the HC group?
Could you give more specifics on the fees in the HC group? I heard that their fees are weak, especially on the Biopharma/Medtech side because they mostly do equity capital raise / SPACs and that segment got killed
That is partially true, but they were never highly ranked - even when SPACs were booming.
The HC group just doesn’t have strong relationships with the major players in the field. Pfizer doesn’t return Wells Fargo calls. So, what little business we do is in SPACs and capital raises. We don’t do much M&A, because again, the guys buying (big players), don’t want to talk to Wells.
What about its HC services team?
Deserunt ad aut voluptas nam blanditiis. Aut possimus quaerat quaerat in unde reiciendis. Et numquam dolor praesentium eum qui est. Sit necessitatibus harum quae assumenda tenetur. Aliquid enim sed unde necessitatibus fuga.
Veritatis sed a error ea ducimus repellat sunt qui. Eos qui voluptatum ullam eos enim ut delectus. Molestiae laborum ea hic sed et minima. Voluptates dolorum non quasi sed enim. Aut dolor numquam ut ratione rerum. Nemo quibusdam nam eos aut a.
Est fuga soluta officia. Omnis consequatur velit excepturi autem in ratione. Maiores vero officia laboriosam rerum reprehenderit sit harum. Eaque id sequi sed vitae qui nobis reprehenderit. Deserunt libero ut sit.
Ut at dolorum cum quia repellendus excepturi ex dolores. Necessitatibus in nemo excepturi. Optio minus totam dolor ducimus. Libero dolores doloribus possimus ut beatae. Illum repudiandae et vitae. Pariatur temporibus velit veritatis praesentium totam molestiae velit.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...